使用非向性脂类药物识别新型精神分裂症相关代谢物
Mengyao Shi1, Xiangdong Du2, Yiming Jia1
1Department of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, 199 Renai Road, Industrial Park District, Suzhou 215123, Jiangsu, China.
Cerebral cortex (New York, N.Y. : 1991)
|April 14, 2024
概括
这项研究确定了34个与中国患者精神分裂症相关的脂质分子. 这些脂质代谢物还与认知功能有关,这表明它们可能具有诊断和治疗作用.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 精神病学是一个精神病学.
背景情况:
- 人体脂质组在精神分裂症中的作用,特别是在中国人群中,仍未得到充分研究.
- 识别新的生物标志物对于理解精神分裂症的生物学基础至关重要.
研究的目的:
- 在中国患者中发现与精神分裂症相关的新型脂质分子.
- 探索这些脂质分子与精神分裂症认知障碍之间的关系.
主要方法:
- 对96名男性精神分裂症患者和96名匹配的健康对照进行了非向性脂质组学分析.
- 后勤回归模型确定了与精神分裂症相关的代谢物.
- 线性回归模型评估了这些代谢物与认知功能的关联.
主要成果:
- 34种脂质代谢物与精神分裂症有显著的关联.
- 这些代谢物改善了精神分裂症风险的重新分类,超出了传统的因素.
- 十个与精神分裂症相关的代谢物与各种认知领域相关,包括记忆,视觉空间技能,语言和注意力.
结论:
- 脂质代谢物代表精神分裂症的潜在新型诊断和治疗点.
- 这项研究通过脂质组分析为精神分裂症的生物机制提供了新的见解.
相关概念视频
Antidepressant Drugs: Overview
2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K


